Hereditary tyrosinaemia type 1

The PBS subsidises nitisinone for patients with hereditary tyrosinaemia type 1 (HT-1).

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with nitisinone under the National Health Act 1953, section 100 for patients with HT-1.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing nitisinone.

Section 100 arrangements

Nitisinone

This item is only PBS-subsidised for non-admitted patients, day admitted patients, or patients on discharge who are attending either:

  • an approved private hospital
  • a public hospital.

This item isn’t PBS-subsidised for public hospital in-patients. You must include the hospital name and provider number on the authority application form.

Treatment specifics

To be eligible for PBS-subsidised treatment with nitisinone, patients must be treated by a physician with expertise in the management of HT-1 in a centre with expertise in genetic metabolic disorders.

Authority applications

Please note: You’ll get an immediate assessment when you request PBS authorities online.

Applying for initial treatment

Applications for initial authority approval to prescribe PBS-subsidised nitisinone to treat HT-1 can be made in:

All written applications must include:

Applying for initial grandfather treatment

Applications for initial grandfather authority approval to prescribe PBS-subsidised nitisinone to treat HT-1 can be made in:

All written applications must include:

Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS-subsidised nitisinone to treat HT-1 can be made either:

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 1 August 2026.
QC 84409